Brexit Trade Deal Must Wait, But UK Medtech Sector Finds Reasons To Be Cheerful
Executive Summary
During the week of the ostensibly pivotal EU Summit on Brexit, the UK government has made the EU27 wait for its white paper on proposed post-EU trading arrangements. The UK medtech industry, in turn, is kept waiting on its EU future. But far from remaining idle, manufacturers are focusing on innovation adoption and working with the NHS, where there is a new sense of purpose, and maybe a light at the end of the tunnel.
You may also be interested in...
MHRA’s Lee To Give UK Medtech Industry Greater Diagnostics Focus
The UK ABHI has created a new role for a director of diagnostics regulation, which MHRA IVD’s policy adviser Steve Lee will fill later this month.
UK HealthTech Ready To Take The Digital Challenge With Focused Actions
Digital tools and maximizing the data derived from them will influence the delivery of health care in ways and to extents yet unknown. Andrew Davies, market access director for UK industry group ABHI, explains the industry's planning around this, and calls for a rethink on innovation market access structures, which are still failing to meet industry's needs.
UK Must Break The Cycle Of Pricing Pressure And Face Up To Medtech Value Needs
The UK Department of Health's new system of medical device procurement for the NHS went live in May. What was the Future Operating Model (FOM) is now simply the "Operating Model." But there are yet to be any tenders under a system that supposedly champions value and total ownership. UK industry wants to believe it, but will it happen? And will Brexit get in the way?